DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology ...

North Carolina, ranked in the top five states for life sciences by Business Facilities, is home to a thriving ecosystem specializing in bio and pharmaceutical manufacturing. Propelled by a low cost of ...

Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and ...

Biotech stocks may offer your portfolio an element of growth, and that's because these companies are sharply focused on innovation. They set out to tackle some of the most challenging diseases, and as ...

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) stands ...

Eli Lilly LLY announced that it has entered into a definitive agreement to acquire U.K.-based Centessa Pharmaceuticals CNTA.

Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.

State Key Laboratory of Pharmaceutical Biotechnology, HKU has the following research output in the current window (1 January 2025 - 31 December 2025) of the Nature Index. Click on Count to view a list ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...